Challenging Drug Resistance in Cancer Therapy: Review of the First Nordic Conference on Chemoresistance in Cancer Treatment, October 9th and 10th, 1997

References

• Skovsgaard T. Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo. Cancer Chemother Rep 1975; 59: 301–8.
   PubMedGoogle Scholar
• Endicott JA, Ling V. The biochemistry of P-glycoprotein-me-diated multidrug resistance. Annu Rev Biochem 1989; 58: 137–71.
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152–62.
   PubMed Web of Science ®Google Scholar
• Breuninger LM, Paul S, Gaughan K, et al. Expression of multidrug resistance-associated protein in NIH/3T3 cells con-fers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 1995; 55: 5342–7.
   PubMed Web of Science ®Google Scholar
• Germann UA, Pastan I, Gottesman MM. P-glycoproteins: mediators of multidrug resistance. Semin Cell Biol 1993; 4: 63–76.
   Google Scholar
• Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650–4.
   PubMed Web of Science ®Google Scholar
• Krishnamachary N, Center MS. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 1993; 53: 3658–61.
   PubMed Web of Science ®Google Scholar
• Zaman GJ, Flens MJ, van Leusden MR, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 1994; 91: 8822–6.
   PubMed Web of Science ®Google Scholar
• Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpres-sion of a M(r) 110,000 vesicular protein in non-P-glyco-protein-mediated multidrug resistance. Cancer Res 1993; 53: 1475–9.
   PubMed Web of Science ®Google Scholar
• Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, van der Valk P, Scheper RJ. Major vault protein LRP-related multidrug resistance. Eur J Cancer 1996; 32A: 979–84.
   Google Scholar
• Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987; 316: 1388–93.
   PubMed Web of Science ®Google Scholar
• Mulder HS, Dekker H, Pinedo HM, Lankelma J. The P-gly-coprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with vary-ing lipophilicity. Biochem Pharmacol 1995; 50: 967–74.
   PubMed Web of Science ®Google Scholar
• Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr 1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586–92.
   Google Scholar
• Campos L, Guyotat D, Archimbaud E, et al. Clinical signifi-cance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473–6.
   PubMed Web of Science ®Google Scholar
• Yuen AR, Sikic BI. Multidrug resistance in lymphomas. J Clin Oncol 1994; 12: 2453–9.
   PubMed Web of Science ®Google Scholar
• Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expres-sion of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome [see comments]. N Engl J Med 1995; 333: 1380–5.
   Google Scholar
• Savaraj N, Wu CJ, Xu R, et al. Multidrug-resistant gene expression in small-cell lung cancer. Am J Clin Oncol 1997; 20: 398–403.
   PubMed Web of Science ®Google Scholar
• Linn SC, Honkoop All, Hoekman K, van der Valk P, Pinedo HM, Giaccone G. p53 and P-glycoprotein are often co-ex-pressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996; 74: 63–8.
   Google Scholar
• Chan HS, Thomer PS, Haddad G, Ling V. Immunohisto-chemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990; 8: 689–704.
   PubMed Web of Science ®Google Scholar
• Chan HS, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991; 325: 1608–14.
   PubMed Web of Science ®Google Scholar
• Ballinger JR, Bannerman J, Boxen I, Firby P, Hartman NG, Moore MJ. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 1996; 37: 1578–82.
   PubMed Web of Science ®Google Scholar
• Andrews DW, Das R, Kim S, Zhang J, Curtis M. Tech-netium-MIBI as a glioma imaging agent for the assessment ofmulti-drug resistance. Neurosurgery 1997; 40: 1323–32; dis-cussion 1333-4.
   Google Scholar
• Derebek E, Kirkali Z, Dogan AS, et al. 99mTc-MIBI scintig-raphy in metastatic renal cell carcinoma: clinical validation of the relationship between 99mTc-MIBI uptake and P-glyco-protein expression in tumour tissue. Eur J Nucl Med 1996; 23: 976–9.
   PubMedGoogle Scholar
• Ambudkar SV, Cardarelli CO, Pashinsky I, Stein WD. Rela-tion between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein. J Biol Chem 1997; 272: 21160–6.
   PubMed Web of Science ®Google Scholar
• Germann UA. P-glycoprotein-a mediator of multidrug re-sistance in tumour cells. Eur J Cancer 1996; 32A: 927–44.
   PubMed Web of Science ®Google Scholar
• Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambud-kar SV. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 1997; 94: 10594–9.
   PubMed Web of Science ®Google Scholar
• Litman T, Zeuthen T, Skovsgaard T, Stein WD. Structure-ac-tivity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Biochim Biophys Acta 1997; 1361: 159–68.
   PubMed Web of Science ®Google Scholar
• Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identifica-tion of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br J Cancer 1997; 75: 869–77.
   Google Scholar
• Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967–72.
   PubMed Web of Science ®Google Scholar
• de Faire U, Lundman T. Attempted suicide with verapamil. Eur J Cardiol 1977; 6: 195–8.
   PubMedGoogle Scholar
• Candell J, Valle V, Soler M, Rius J. Acute intoxication with verapamil. Chest 1979; 75: 200–1.
   PubMed Web of Science ®Google Scholar
• Slater LM, Sweet P, Stupecky M, Gupta S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 1986; 77: 1405–8.
   PubMed Web of Science ®Google Scholar
• Meador J, Sweet P, Stupecky M, et al. Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129. Cancer Res 1987; 47: 6216–9.
   PubMed Web of Science ®Google Scholar
• Theis JGW, Chan HSL, Greenberg ML, et al. Chemotherapy combined with the P-glycoprotein inhibitor Cyclosporin (CsA) in children: assessment of the systemic toxicity. Eur J Clin Pharmacol 1997; 52 (Suppl.): A102.
   Google Scholar
• Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991; 51: 4226–33.
   Google Scholar
• Boesch D, Muller K, Pourtier-Manzanedo A, Loor F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res 1991; 196: 26–32.
   Google Scholar
• Lum BL, Gosland MP. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glyco-protein inhibitors. Hematol Oncol Clin North Am 1995; 9: 319–36.
   Google Scholar
• Liliemark J, Bjorkholm M, Uden A-M, et al. SDZ PSC 833 (PSC) in combination with daunorubicin (D) and Cytarabine in refractory acute myelogenous leukemia (AML). Blood 1996; 88 (Suppl. 1): 216a.
   Google Scholar
• Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-re-sistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695–8.
   PubMed Web of Science ®Google Scholar
• Tatsuta T, Naito M, Oh-hara T, Sugawara I, Tsuruo T. Functional involvement of P-glycoprotein in blood-brain bar-rier. J Biol Chem 1992; 267: 20383–91.
   Google Scholar
• Drach J, Gsur A, Hamilton G, et al. Involvement of P-glyco-protein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996; 88: 1747–54.
   PubMed Web of Science ®Google Scholar
• Raghu G, Park SW, Roninson IB, Mechetner EB. Mono-clonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp Hematol 1996; 24: 1258–64.
   PubMed Web of Science ®Google Scholar
• O'Brien ML, Tew KD. Glutathione and related enzymes in multidrug resistance. Eur J Cancer 1996; 32A: 967–78.
   PubMed Web of Science ®Google Scholar
• Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988; 241: 1813–5.
   PubMed Web of Science ®Google Scholar
• Rugstad HE. Metallothionein-a unique protein with multi-ple detoxifying properties? Eur Surg Res 1984; 16 (Suppl. 2): 102–12.
   Google Scholar
• Leyshon-Sorland K, Morkrid L, Rugstad HE. Metalloth-ionein: a protein conferring resistance in vitro to tumor necrosis factor. Cancer Res 1993; 53: 4874–80.
   Google Scholar
• Goulding H, Jasani B, Pereira H, et al. Metallothionein expression in human breast cancer. Br J Cancer 1995; 72: 968–72.
   PubMed Web of Science ®Google Scholar
• Hishikawa Y, Abe S, Kinugasa S, et al. Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. Oncology 1997; 54: 342–7.
   PubMed Web of Science ®Google Scholar
• Chin JL, Banerjee D, Kadhim SA, Kontozoglou TE, Chauvin PJ, Cherian MG. Metallothionein in testicular germ cell tu-mors and drug resistance. Clinical correlation. Cancer 1993; 72: 3029–35.
   Google Scholar
• Gerson SL, Willson JK. 06-alkylguanine-DNA alkyltrans-ferase. A target for the modulation of drug resistance. Hema-tol Oncol Clin North Am 1995; 9: 431–50.
   PubMed Web of Science ®Google Scholar
• Gerson SL, Berger SJ, Varnes ME, Donovan C. Combined depletion of 06-alkylguanine-DNA alkyltransferase and glu-tathione to modulate nitrosourea resistance in breast cancer. Biochem Pharmacol 1994; 48: 543–8.
   PubMed Web of Science ®Google Scholar
• Pegg AE. Methylation of the 06 position of guanine in DNA is the most likely initiating event in carcinogenesis by methy-lating agents. Cancer Invest 1984; 2: 223–31.
   PubMed Web of Science ®Google Scholar
• Gerson SL, Miller K, Berger NA. 06 alkylguanine-DNA alkyltransferase activity in human myeloid cells. J Clin Invest 1985; 76: 2106–14.
   PubMed Web of Science ®Google Scholar
• Grafstrom RC, Pegg AE, Trump BF, Harris CC. 06-alkyl-guanine-DNA alkyltransferase activity in normal human tis-sues and cells. Cancer Res 1984; 44: 2855–7.
   PubMed Web of Science ®Google Scholar
• Citron M, Decker R, Chen S, et al. 06-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary. Cancer Res 1991; 51: 4131–4.
   PubMed Web of Science ®Google Scholar
• Citron M, Graver M, Schoenhaus M, et al. Detection of messenger RNA from 06-methylguanine-DNA methyltrans-ferase gene MGMT in human normal and tumor tissues. J Natl Cancer Inst 1992; 84: 337–40.
   PubMed Web of Science ®Google Scholar
• Hansson J, Martenhed G, Egyhazi S, Tani E, Platz A. Analy-sis of 06-methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction. Eur J Cancer 1996; 32A: 2319–26.
   Google Scholar
• Egyhazi S, Margison GP, Hansson J, Ringborg U. Immuno-histochemical examination of the expression of 06-methyl-guanine-DNA methyltransferase in human melanoma metastases. Eur J Cancer 1997; 33: 129–34.
   PubMed Web of Science ®Google Scholar
• Gerson SL, Zborowska E, Norton K, Gordon NH, Willson JK. Synergistic efficacy of 06-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. Biochem Pharmacol 1993; 45: 483–91.
   Google Scholar
• Felker GM, Friedman HS, Dolan ME, Moschel RC, Schold C. Treatment of subcutaneous and intracranial brain tumor xenografts with 06-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol 1993; 32: 471–6.
   Google Scholar
• Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456–62.
   PubMed Web of Science ®Google Scholar
• Reed JC, Miyashita T, Takayama S, et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996; 60: 23–32.
   PubMed Web of Science ®Google Scholar
• Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992; 11: 121–39.
   PubMed Web of Science ®Google Scholar
• Mesner PW Jr, Budihardjo II, Kaufmann SH. Chemotherapy-induced apoptosis. Adv Pharmacol 1997; 41: 461–99.
   Google Scholar
• Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267: 1445–9.
   PubMed Web of Science ®Google Scholar
• Campos L, Rouault JP, Sabido O, et al. High expression of bc1-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091–6.
   Google Scholar
• Nakamura S, Akazawa K, Kinukawa N, Yao T, Tsuneyoshi M. Inverse correlation between the expression of bc1-2 and p53 proteins in primary gastric lymphoma. Hum Pathol 1996; 27: 225–33.
   Google Scholar
• Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G. bc1-2 and other genomic alterations in the prog-nosis of large-cell lymphoma. N Engl J Med 1989; 320: 1047–54.
   PubMed Web of Science ®Google Scholar
• Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 1997; 90: 3118–29.
   Google Scholar
• Walker A, Taylor ST, Hickman JA, Dive C. Germinal center-derived signals act with Bc1-2 to decrease apoptosis and increase clonogenicity of drug-treated human B lymphoma cells. Cancer Res 1997; 57: 1939–45.
   PubMed Web of Science ®Google Scholar
• Gjertsen BT, Cressey LI, Ruchaud S, Houge G, Lanotte M, Doskeland SO. Multiple apoptotic death types triggered through activation of separate pathways by cAMP and in-hibitors of protein phosphatases in one (IPC leukemia) cell line. J Cell Sci 1994; 107: 3363–77.
   PubMed Web of Science ®Google Scholar
• Vintermyr OK, Gjertsen BT, Lanotte M, Doskeland SO. Microinjected catalytic subunit of cAMP-dependent protein kinase induces apoptosis in myeloid leukemia (IPC-81) cells. Exp Cell Res 1993; 206: 157–61.
   PubMed Web of Science ®Google Scholar
• Jansen B, Schlagbauer-Wadl H, Brown B, et al. Bc1-2 anti-sense therapy chemosensitizes human melanoma in SCID mice. Nature Med 1998; 4: 232–4.
   PubMed Web of Science ®Google Scholar
• Lotem J, Sachs L. Regulation by bc1-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 1993; 4: 41–7.
   PubMedGoogle Scholar
• Velculescu YE, El-Deiry WS. Biological and clinical impor-tance of the p53 tumor suppressor gene. Clin Chem 1996; 42: 858–68.
   PubMed Web of Science ®Google Scholar
• Gallagher WM, Cairney M, Schott B, Roninson IB, Brown R. Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene 1997; 14: 185–93.
   Google Scholar
• Aas T, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996; 2: 811–4.
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV, El-Deiry WS. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int .1- Cancer 1996; 67: 386–92.
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54: 2287–91.
   Google Scholar
• Zakian VA. Telomeres: beginning to understand the end. Science 1995; 270: 1601–7.
   PubMed Web of Science ®Google Scholar
• Clark GM, Osborne CK, Levitt D, Wu F, Kim NW. Telom-erase activity and survival of patients with non-positive breast cancer. J Natl Cancer Inst 1997; 89: 1874–81.
   PubMed Web of Science ®Google Scholar
• Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric micro-culture cytotoxicity assay (FMCA). Int .1- Cancer 1992; 50: 177–85.
   PubMed Web of Science ®Google Scholar
• Twentyman PR, Fox NE, Rees JK. Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay. Br J Haematol 1989; 71: 19–24.
   Google Scholar
• Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods 1991; 142: 257–65.
   PubMed Web of Science ®Google Scholar
• Tan KB, Mattern MR, Eng WK, McCabe FL, Johnson RK. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 1989; 81: 1732–5.
   Google Scholar
• Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 1989; 49: 58–62.
   Google Scholar
• Takano H, Kohno K, Ono M, Uchida Y, Kuwano M.Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 1991; 51: 3951–7.
   Google Scholar
• Chu E, Drake JC, Koeller DM, et al. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 1991; 39: 136–43.
   PubMed Web of Science ®Google Scholar
• Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 1995; 49: 1419–26.
   Google Scholar
• Horikoshi T, Danenberg KD, Stadlbauer TH, et al. Quantita-tion of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res 1992; 52: 108–16.
   PubMed Web of Science ®Google Scholar
• Houze TA, Larsson L, Larsson PA, Hansson G, Gustavsson B. Detection of thymidylate synthase gene expression levels in formalin-fixed paraffin embedded tissue by semiquantitative, nonradioactive reverse transcriptase polymerase chain reaction. Tumour Biol 1997; 18: 53–68.
   Google Scholar
• Larsson PA, Carlsson G, Gustavsson B, Spears CP. Thymidy-late synthase in advanced gastrointestinal and breast cancers. Acta Oncol 1996; 35: 469–72.
   PubMed Web of Science ®Google Scholar
• Dohden K, Ohmura K, Watanabe Y. Ternary complex forma-tion and reduced folate in surgical specimens of human adenocarcinoma tissues. Cancer 1993; 71: 471–80.
   Google Scholar
• Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ. Fluorouracil and high-dose leucovorin in previ-ously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 890–9.
   PubMed Web of Science ®Google Scholar
• Larsson PA, Carlsson G, Gustavsson B, Graf W, Glimelius B. Different intravenous administration techniques for 5-fluorou-racil. Pharmacokinetics and pharmacodynamic effects. Acta Oncol 1996; 35: 207–12.
   Google Scholar